Intellia Therapeutics Announces Third Quarter 2021 Financial ...

Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress · $20.7 million to · $60.5 million ...

Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress. Intellia Therapeutics, Inc. Thu, Nov 4, 2021 16 ...

Intellia Therapeutics to Hold Conference Call to Discuss Third ...

(NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in ...

Intellia Therapeutics Announces Third Quarter 2021 Financial ...

Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress ... CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) ...

Intellia Therapeutics Announces Third Quarter 2021 Financial ...

PM360 embraces diversity, gender equality, ideas, and innovation that advance bold ideas in pharmaceutical marketing. PM360 is the premier magazine for ...

Press Releases - Intellia Therapeutics

Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress ... 2021 European Society of Gene & Cell Therapy ...

Intellia Therapeutics Announces Third Quarter 2021 Financial ...

Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress. Start Trading Futures.

Intellia Therapeutics Announces Third Quarter 2022 Financial ...

$848.7 million as of September 30, 2022 , compared to ; $1.1 billion as of December 31, 2021 . The decrease was driven by cash used to fund ...

Intellia Therapeutics - investor relations

Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress. Read More · View All Press Releases. Upcoming

Intellia Therapeutics Announces Third Quarter 2024 Financial ...

Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress ; $944.7 million as of September 30, ...

Intellia Therapeutics Announces Second Quarter 2021 Financial ...

Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 ...

Press Releases - Intellia Therapeutics - investor relations

Third quarter 2024 financial results – November 7 , at 8 a.m. ET New clinical data from the Phase 1 study of nexiguran ziclumeran (nex-z) for the treatment of ...

Intellia Therapeutics Announces Fourth Quarter and - GlobeNewswire

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company Progress ; Loss from equity ...

Regeneron Reports Third Quarter 2022 Financial and Operating ...

Total revenues decreased 15% to $2.936 billion in the third quarter of 2022, compared to $3.453 billion in the third quarter of 2021.

Intellia Therapeutics Announces Third Quarter 2022 Financial ...

Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress ; Total other (expense) income, net ...

NTLA SEC Filings - Intellia Therapeutics, Inc.- Annual Report, Proxy ...

2024-06-14, Intellia Therapeutics Names Brian Goff to its Board of Directors) ; 2024-05-09, Intellia Therapeutics Announces First Quarter 2024 Financial Results ...

Press Releases - CRISPR Therapeutics

... Therapy for Treatment of Type 1 Diabetes. Nov 03, 2021. CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results. Nov 02, ...

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results ...

Net cash used in operating activities was $6.6 million for the nine months ended September 30, 2024 compared to $12.2 million for the same ...

Spyre Therapeutics Reports Third Quarter 2024 Financial Results ...

The company has $414 million in cash, cash equivalents, and marketable securities as of September 30, 2024, with an expected runway into 2027.

Intellia Therapeutics to Hold Conference Call to Discuss Third ...

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing ...